MHLW approves Novartis Kymriah (tisagenlecleucel) for treatment of 2 different indications
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Novartis, the SwissPharmaceutical(http://giant, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Kymriah (tisagenleleucel) for treatment of two different indications: CD19-positive recurrent or refractory (R/R) B-cell acute lymphoblastoma (ALLLB)MHLW reviewed data from globally registered CAR-T clinical studies JULIET and ELIANA, including research sites in JapanIn these studies, Kymriah showed strong and long-lasting response rates and consistent safety in two different groups of patients with difficultyTo date, two CAR-T cell therapies have been approved worldwide, one for Kymriah and the other for Gilead's YescartaUnlike conventional small molecule or biotherapy, CAR-T cell therapy is a living T-cell therapyproduct(http://Kymriah and Yescarta are both genetically modified and genetically modified of the patient's T cells to express a chimeric antigen receptor (CAR) designed to target antigen CD19, an antigen protein that is expressed on the surface of a variety of blood tumor cells, including B-cell lymphoma and leukemia cells
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
